Aquestive Therapeutics (AQST) Assets Average (2018 - 2026)

Aquestive Therapeutics has reported Assets Average for 9 years, with the latest figure at $136.6 million in Q2 2026.

• On a quarterly basis, Assets Average rose 39.45% year-over-year to $136.6 million in Q2 2026; TTM through Jun 2026 was $136.6 million, a 39.45% increase from a year earlier, with the FY2025 full-year figure at $130.9 million, up 64.85% from the prior year.
• Assets Average was $136.6 million for Q2 2026 at Aquestive Therapeutics, down from $150.8 million in the prior quarter.
• The five-year high for Assets Average was $162.0 million in Q4 2025, with the low at $54.1 million in Q3 2022.
• Average Assets Average over 5 years is $93.0 million, with a median of $95.7 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Assets Average surged 108.94% in 2024, then decreased 20.72% in 2025.
• Over 5 years, Assets Average stood at $54.5 million in 2022, then grew by 7.3% to $58.4 million in 2023, then soared by 80.88% to $105.7 million in 2024, then soared by 53.27% to $162.0 million in 2025, then decreased by 15.67% to $136.6 million in 2026.
• The last three Assets Average figures came in at $136.6 million (Q2 2026), $150.8 million (Q1 2026), and $162.0 million (Q4 2025), per Business Quant data.